Clinical Trials Browser

Completed × NETWORK × talazoparib × Clear all

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT03377556 2021-06-23

Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2 Completed

51 enrolled 18 charts

ATM Gene Mutation